<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00398216</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-PRT011</org_study_id>
    <secondary_id>2006-000758-29</secondary_id>
    <nct_id>NCT00398216</nct_id>
  </id_info>
  <brief_title>A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery</brief_title>
  <official_title>A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      This study is to assess if DU176b is effective in prevention of blood clots following hip
      replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up
      visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjudicated Incidence of VTE</measure>
    <time_frame>end of treatment</time_frame>
    <description>Assess the efficacy of DU-176b in the prevention of venous thromboembolism (VTE) from 6 to 8 hours after hip replacement surgery to 7 to 10 days after the surgery.
A subject was judged to have a VTE if one or more of the following criteria were met:
Observed lower extremity deep vein thrombosis (DVT) (either proximal, distal, or both ) as assessed by bilateral or unilateral ascending contrast venography prior to or at the end-of-treatment (EOT) visit
Symptomatic and objectively proven pulmonary embolism prior to or at the EOT visit
Symptomatic and objectively proven DVT prior to or at EOT visit end of treatment defined as 6 to 8 hours after after hip replacement surgery to 7 to 10 days after the surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Prothrombin Time (PT) From Baseline</measure>
    <time_frame>end of treatment</time_frame>
    <description>change in prothrombin time (PT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Activated Partial Thromboplastin Time (aPTT) From Baseline</measure>
    <time_frame>end of treatment</time_frame>
    <description>change in Activated Partial Thromboplastin Time (aPTT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated Incidence of Major or Clinically Relevant Non-major Bleeding Events</measure>
    <time_frame>10 days after first dose</time_frame>
    <description>adjudicated incidence of major or clinically relevant non-major bleeding events through 10 days after first dose</description>
  </secondary_outcome>
  <enrollment type="Actual">903</enrollment>
  <condition>Thrombosis</condition>
  <condition>Hip Replacement</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. 18 years of age or older; male or female.

          2. Able to provide written informed consent.

          3. Must be scheduled for elective unilateral total hip replacement surgery. Only primary
             surgeries accepted.

          4. If female, must be either one year post-menopausal, surgically sterile, or using
             medically accepted contraceptive measures as judged by the Investigator and in
             accordance with local regulatory requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitchner</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Velikij Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chernivtsy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>February 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2015</results_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <name_title>Anne MacDonald</name_title>
    <organization>Daiichi Sankyo</organization>
  </responsible_party>
  <keyword>Anti-coagulant</keyword>
  <keyword>hip replacement</keyword>
  <keyword>hip replacement surgery</keyword>
  <keyword>unilateral hip replacement surgery</keyword>
  <keyword>DeepVein Thrombosis</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>pulmonary embolism</keyword>
  <keyword>Prevention of Blood Clots</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Factor Xa Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Edoxaban 15mg QD</title>
          <description>edoxaban 15mg QD (once daily) orally (PO)</description>
        </group>
        <group group_id="P2">
          <title>Edoxaban 30mg QD</title>
          <description>edoxaban 30mg QD PO</description>
        </group>
        <group group_id="P3">
          <title>Edoxaban 60mg QD</title>
          <description>edoxaban 60mg QD PO</description>
        </group>
        <group group_id="P4">
          <title>Edoxaban 90mg QD</title>
          <description>edoxaban 90mg QD PO</description>
        </group>
        <group group_id="P5">
          <title>Dalteparin</title>
          <description>dalteparin 2500 IU/mL initial dose followed by 5000 IU once daily subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="170"/>
                <participants group_id="P3" count="185"/>
                <participants group_id="P4" count="177"/>
                <participants group_id="P5" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="155"/>
                <participants group_id="P5" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Edoxaban 15mg QD</title>
          <description>edoxaban 15mg QD (once daily) orally (PO)</description>
        </group>
        <group group_id="B2">
          <title>Edoxaban 30mg QD</title>
          <description>edoxaban 30mg QD PO</description>
        </group>
        <group group_id="B3">
          <title>Edoxaban 60mg QD</title>
          <description>edoxaban 60mg QD PO</description>
        </group>
        <group group_id="B4">
          <title>Edoxaban 90mg QD</title>
          <description>edoxaban 90mg QD PO</description>
        </group>
        <group group_id="B5">
          <title>Dalteparin</title>
          <description>dalteparin 2500 IU/mL initial dose followed by 5000 IU once daily subcutaneously</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="170"/>
            <count group_id="B3" value="185"/>
            <count group_id="B4" value="177"/>
            <count group_id="B5" value="172"/>
            <count group_id="B6" value="896"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="126"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="110"/>
                    <measurement group_id="B6" value="587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="63"/>
                    <measurement group_id="B5" value="62"/>
                    <measurement group_id="B6" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="12.49"/>
                    <measurement group_id="B2" value="57.2" spread="12.28"/>
                    <measurement group_id="B3" value="58.3" spread="11.52"/>
                    <measurement group_id="B4" value="58.5" spread="12.27"/>
                    <measurement group_id="B5" value="57.5" spread="12.43"/>
                    <measurement group_id="B6" value="57.8" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="105"/>
                    <measurement group_id="B6" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="178"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="165"/>
                    <measurement group_id="B6" value="874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="144"/>
                    <measurement group_id="B5" value="143"/>
                    <measurement group_id="B6" value="748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjudicated Incidence of VTE</title>
        <description>Assess the efficacy of DU-176b in the prevention of venous thromboembolism (VTE) from 6 to 8 hours after hip replacement surgery to 7 to 10 days after the surgery.
A subject was judged to have a VTE if one or more of the following criteria were met:
Observed lower extremity deep vein thrombosis (DVT) (either proximal, distal, or both ) as assessed by bilateral or unilateral ascending contrast venography prior to or at the end-of-treatment (EOT) visit
Symptomatic and objectively proven pulmonary embolism prior to or at the EOT visit
Symptomatic and objectively proven DVT prior to or at EOT visit end of treatment defined as 6 to 8 hours after after hip replacement surgery to 7 to 10 days after the surgery.</description>
        <time_frame>end of treatment</time_frame>
        <population>per protocol analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban 15mg QD</title>
            <description>edoxaban 15mg QD (once daily) orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>Edoxaban 30mg QD</title>
            <description>edoxaban 30mg QD PO</description>
          </group>
          <group group_id="O3">
            <title>Edoxaban 60mg QD</title>
            <description>edoxaban 60mg QD PO</description>
          </group>
          <group group_id="O4">
            <title>Edoxaban 90mg QD</title>
            <description>edoxaban 90mg QD PO</description>
          </group>
          <group group_id="O5">
            <title>Dalteparin</title>
            <description>dalteparin 2500 IU/mL initial dose followed by 5000 IU once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Incidence of VTE</title>
          <description>Assess the efficacy of DU-176b in the prevention of venous thromboembolism (VTE) from 6 to 8 hours after hip replacement surgery to 7 to 10 days after the surgery.
A subject was judged to have a VTE if one or more of the following criteria were met:
Observed lower extremity deep vein thrombosis (DVT) (either proximal, distal, or both ) as assessed by bilateral or unilateral ascending contrast venography prior to or at the end-of-treatment (EOT) visit
Symptomatic and objectively proven pulmonary embolism prior to or at the EOT visit
Symptomatic and objectively proven DVT prior to or at EOT visit end of treatment defined as 6 to 8 hours after after hip replacement surgery to 7 to 10 days after the surgery.</description>
          <population>per protocol analysis set</population>
          <units>percentage of participants with VTE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="139"/>
                <count group_id="O5" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="22.2" upper_limit="36.7"/>
                    <measurement group_id="O2" value="20.3" lower_limit="14.0" upper_limit="27.8"/>
                    <measurement group_id="O3" value="15.7" lower_limit="10.3" upper_limit="22.4"/>
                    <measurement group_id="O4" value="11.5" lower_limit="6.7" upper_limit="18.0"/>
                    <measurement group_id="O5" value="46.0" lower_limit="37.4" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Prothrombin Time (PT) From Baseline</title>
        <description>change in prothrombin time (PT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery</description>
        <time_frame>end of treatment</time_frame>
        <population>perp protocol analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban 15mg QD</title>
            <description>edoxaban 15mg QD (once daily) orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>Edoxaban 30mg QD</title>
            <description>edoxaban 30mg QD PO</description>
          </group>
          <group group_id="O3">
            <title>Edoxaban 60mg QD</title>
            <description>edoxaban 60mg QD PO</description>
          </group>
          <group group_id="O4">
            <title>Edoxaban 90mg QD</title>
            <description>edoxaban 90mg QD PO</description>
          </group>
          <group group_id="O5">
            <title>Dalteparin</title>
            <description>dalteparin 2500 IU/mL initial dose followed by 5000 IU once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Prothrombin Time (PT) From Baseline</title>
          <description>change in prothrombin time (PT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery</description>
          <population>perp protocol analysis set</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="146"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".90" spread="3.205"/>
                    <measurement group_id="O2" value="1.07" spread="1.875"/>
                    <measurement group_id="O3" value="2.87" spread="6.279"/>
                    <measurement group_id="O4" value="2.74" spread="5.821"/>
                    <measurement group_id="O5" value=".67" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Activated Partial Thromboplastin Time (aPTT) From Baseline</title>
        <description>change in Activated Partial Thromboplastin Time (aPTT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery</description>
        <time_frame>end of treatment</time_frame>
        <population>perp protocol analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban 15mg QD</title>
            <description>edoxaban 15mg QD (once daily) orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>Edoxaban 30mg QD</title>
            <description>edoxaban 30mg QD PO</description>
          </group>
          <group group_id="O3">
            <title>Edoxaban 60mg QD</title>
            <description>edoxaban 60mg QD PO</description>
          </group>
          <group group_id="O4">
            <title>Edoxaban 90mg QD</title>
            <description>edoxaban 90mg QD PO</description>
          </group>
          <group group_id="O5">
            <title>Dalteparin</title>
            <description>dalteparin 2500 IU/mL initial dose followed by 5000 IU once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Activated Partial Thromboplastin Time (aPTT) From Baseline</title>
          <description>change in Activated Partial Thromboplastin Time (aPTT) from baseline to end of treatment end of treatment defined as 6-8 hours after hip replacement surgery to 7 to 10 days after the surgery</description>
          <population>perp protocol analysis set</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="134"/>
                <count group_id="O5" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="6.562"/>
                    <measurement group_id="O2" value="1.67" spread="13.092"/>
                    <measurement group_id="O3" value="4.39" spread="16.930"/>
                    <measurement group_id="O4" value="3.26" spread="13.169"/>
                    <measurement group_id="O5" value="2.34" spread="12.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjudicated Incidence of Major or Clinically Relevant Non-major Bleeding Events</title>
        <description>adjudicated incidence of major or clinically relevant non-major bleeding events through 10 days after first dose</description>
        <time_frame>10 days after first dose</time_frame>
        <population>safety analysis dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Edoxaban 15mg QD</title>
            <description>edoxaban 15mg QD (once daily) orally (PO)</description>
          </group>
          <group group_id="O2">
            <title>Edoxaban 30mg QD</title>
            <description>edoxaban 30mg QD PO</description>
          </group>
          <group group_id="O3">
            <title>Edoxaban 60mg QD</title>
            <description>edoxaban 60mg QD PO</description>
          </group>
          <group group_id="O4">
            <title>Edoxaban 90mg QD</title>
            <description>edoxaban 90mg QD PO</description>
          </group>
          <group group_id="O5">
            <title>Dalteparin</title>
            <description>dalteparin 2500 IU/mL initial dose followed by 5000 IU once daily subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Adjudicated Incidence of Major or Clinically Relevant Non-major Bleeding Events</title>
          <description>adjudicated incidence of major or clinically relevant non-major bleeding events through 10 days after first dose</description>
          <population>safety analysis dataset</population>
          <units>percentage of subjects with bleed events</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="185"/>
                <count group_id="O4" value="177"/>
                <count group_id="O5" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.3" upper_limit="4.5"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.1"/>
                    <measurement group_id="O3" value="2.2" lower_limit="0.6" upper_limit="5.4"/>
                    <measurement group_id="O4" value="2.3" lower_limit="0.6" upper_limit="5.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.250</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.122</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.124</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.123</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Edoxaban 15mg QD</title>
          <description>edoxaban 15mg QD (once daily) orally (PO)</description>
        </group>
        <group group_id="E2">
          <title>Edoxaban 30mg QD</title>
          <description>edoxaban 30mg QD PO</description>
        </group>
        <group group_id="E3">
          <title>Edoxaban 60mg QD</title>
          <description>edoxaban 60mg QD PO</description>
        </group>
        <group group_id="E4">
          <title>Edoxaban 90mg QD</title>
          <description>edoxaban 90mg QD PO</description>
        </group>
        <group group_id="E5">
          <title>Dalteparin</title>
          <description>dalteparin 2500 IU/mL initial dose followed by 5000 IU once daily subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>secretion of discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>fat embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>incision site hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>post-procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>wound hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="172"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="172"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study site’s proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Maxwell, Assoc. Director</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>732-590-5000</phone>
      <email>wmaxwell@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

